1. Home
  2. AEF vs SGHT Comparison

AEF vs SGHT Comparison

Compare AEF & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AEF

abrdn Emerging Markets Equity Income Fund Inc.

HOLD

Current Price

$7.38

Market Cap

315.9M

Sector

Finance

ML Signal

HOLD

Logo Sight Sciences Inc.

SGHT

Sight Sciences Inc.

HOLD

Current Price

$3.49

Market Cap

187.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEF
SGHT
Founded
1989
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
315.9M
187.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
AEF
SGHT
Price
$7.38
$3.49
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$9.08
AVG Volume (30 Days)
192.3K
368.5K
Earning Date
01-01-0001
05-07-2026
Dividend Yield
7.13%
N/A
EPS Growth
N/A
28.16
EPS
0.57
N/A
Revenue
N/A
$77,363,000.00
Revenue This Year
N/A
$11.81
Revenue Next Year
N/A
$10.62
P/E Ratio
$13.16
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.43
$2.03
52 Week High
$8.93
$9.24

Technical Indicators

Market Signals
Indicator
AEF
SGHT
Relative Strength Index (RSI) 44.81 34.90
Support Level $6.10 $3.29
Resistance Level $8.09 $3.76
Average True Range (ATR) 0.21 0.22
MACD -0.01 0.06
Stochastic Oscillator 48.98 7.86

Price Performance

Historical Comparison
AEF
SGHT

About AEF abrdn Emerging Markets Equity Income Fund Inc.

ABERDEEN EMERGING MARKETS EQUITY INCOME FUND, INC. is a closed-end investment company. The Fund's investment objective is to seek to provide both current income and long-term capital appreciation. The Fund invests in a range of sectors, including financials, consumer staples, utilities, consumer discretionary, materials, energy, information technology, private equity, communication services, healthcare, real estate, and industrials.

About SGHT Sight Sciences Inc.

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.

Share on Social Networks: